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Summary Brequinar sodium (DUP-785; Brequinar) is a potent inhibitor of the pyrimidine de novo enzyme
dihydroorotate dehydrogenase (DHO-DH), leading to a depletion of pyrimidine nucleotides, which could be
reversed by uridine. In in vitro studies we investigated the effect of different physiological concentrations of
uridine on the growth-inhibition by Brequinar, the effect of the nucleoside transport inhibitor, dipyridamole,
and the combination of Brequinar and 5-fluorouracil (5FU). Uridine at 1 gLM slightly reversed the growth
inhibition by Brequinar, while the effect of 5-500 gM was greater. However, at Brequinar concentrations
> 30gM, uridine could not reverse the growth-inhibitory effects. Addition ofdipyridamole could only partially
prevent the reversing effects of uridine. The combination of Brequinar and 5FU was more than additive in the
absence of uridine in the culture medium, but not in the presence of uridine. The combination of Brequinar
and 5FU was tested in vivo in two murine colon tumour models, Colon 26 and Colon 38. Scheduling of both
compounds appeared to be very important. In Colon 38 no potentiating effect of Brequinar could be observed.
In contrast in Colon 26 a more than additive effect could be observed. Since uridine concentrations are
considerably different in these tumours (higher in Colon 38), it was concluded from both the in vitro and in
vivo experiments that uridine is an important determinant in combinations of Brequinar and 5FU.
Brequinar Sodium (Brequinar; DUP-785; NSC 368390) is a
potent inhibitor of dihydroorotic acid dehydrogenase (DHO-
DH), the fourth enzyme in the de novo pyrimidine nucleotide
synthesis (Figure 1) which is located on the outer site of the
inner membrane of the mitochondrion (Chen et al., 1986;
Peters et al., 1987a). The Ki varies between 10 and 100 nM
depending on the source of the enzyme. Brequinar is a
4-quinoline carboxylic acid with significant antitumour
activity in experimental tumours (Dexter et al., 1985; Braak-
huis et al., 1990) which was therefore selected for clinical
Phase I and II investigations (Arteaga et al., 1989; Bork et
al., 1989; Dodion et al., 1990; Noe et al., 1990; Schwarts-
mann et al., 1990). The maximum tolerated dose (MTD)
proved to be 1,800 mg m2. A weekly treatment schedule
showed no activity against a number of solid tumours
(Dodion et al., 1990); the compound showed acceptable toxi-
city at the dose level 1,200 mgm2. Biochemical effects of
Brequinar at the dose range from 600-2,250 mg m-2 (Peters
et al., 1990a) were related to the toxicity of the drug and
consisted of the inhibition of DHO-DH and a depletion of
pyrimidine nucleotides in lymphocytes of the patients; in
plasma uridine levels decreased followed by a rebound.
Biochemical effects observed in patients were comparable to
those in mice and in vitro (Peters et al., 1987a; 1990b;
Schwartsmann et al., 1988). Drug exposure resulted in
accumulation of cells in the S phase (Schwartsmann et al.,
1988). Growth-inhibitory effects of Brequinar could be
prevented and reversed by addition of uridine or cytidine
(Peters et al., 1987a; Schwartsmann et al., 1988), but not by
thymidine or deoxycytidine. Depletion of pyrimidine deoxy-
ribonucleotides was proportional to that of the ribo-
nucleotides (Schwartsmann et al., 1988), while both could be
reversed by uridine.
Inhibition of the pyrimidine de novo pathway can enhance
the anti-tumour activity of 5FU; both acivicin and N-
phosphonacetyl-L-aspartate (PALA) have been investigated
in preclinical in vitro and in vivo studies (Martin et al., 1983;
Grem et al., 1988; Spiegelman et al., 1980). In initial trials
the MTD of PALA was used while the dose of 5FU was
HCO3 + ATP
Carb-P
Carb-asp
DHO
LDUP785 _I
FUMP UMPJ UR . UR
FUDP UDPJ r
z z a) |~~~~Dipyridao
FUTP UTPj / _ ~~~E
= 0)
RNA * CTP
Figure 1 Schematic representation of pyrimidine metabolism,
showing the effects of inhibition by Brequinar (DUP-785) which
may affect the metabolism of 5FU; arrows indicate an increase of
PRPP (phosphoribosyl-pyrophosphate) or a decrease of
pyrimidine nucleotides and OA (orotic acid). In addition the
possible role of the nucleoside transport inhibitor dipyridamol is
shown. For comparison, PALA can inhibit the conversion of
Carb-P (carbamyl-phosphate) to Carb-asp (carbamyl-aspartate)
and pyrazofurin that of OA to OMP and UMP. UR, uridine.
lowered (Grem et al., 1988; Martin et al., 1985; Casper et al.,
1983). However, a PALA dose of far below that recom-
mended for Phase II trials, yet leading to a depletion of
pyrimidine nucleotides, was sufficient to modulate 5FU
activity (Martin et al., 1985). In a Phase II trial such a dose
of PALA was selected and the dose of 5FU was escalated
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leading to a high response rate (O'Dwyer et al., 1990). In
addition to the encouraging results (30-40% response rate)
with the combination leucovorin and 5FU (Arbuck et al.,
1989) these data demonstrate that principles of biochemical
modulation developed preclinically can be applied success-
fully in the clinic. However, conventional guidelines used for
Phase II trials, should not be applied when the dose of the
modifier is being selected (Leyland-Jones et al., 1986).
In vitro studies should take in vivo conditions into con-
sideration. An example of such conditions is the relatively
high in vivo concentration of uridine in tissues compared to
e.g. plasma (Darnowski et al., 1986; Peters et al., 1987b); this
might affect the antitumour activity of Brequinar. In vitro
this is reflected by the higher sensitivity of cell lines cultured
in dialysed serum compared to culturing in non-dialysed
serum (Peters et al., 1987a), which contains a considerable
amount of uridine. Since Brequinar can decrease pyrimidine
nucleotides both in vitro and in vivo (Chen et al., 1986; Peters
et al., 1990b; Schwartsmann et al., 1988; Anderson et al.,
1989), the compound theoretically can enhance the activity of
5FU. We evaluated this combination both in vitro and in
vivo; while simulating in vivo conditions for in vitro
experiments.
Materials and methods
Materials
Brequinar sodium (DUP 785, NSC 368390) was synthesised
and obtained from the Medicinal Chemistry Section, DuPont
Pharmaceuticals, Wilmington, Delaware, USA, and for-
mulated as a 10 mgml' solution in saline. 5FU was from
Hoffmann-La Roche, Mijdrecht, The Netherlands, and
formulated as a 10 mg ml-l solution. Uridine and 3-(4,5-
dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) were obtained from Sigma, Ohio. Other compounds
were of analytical grade quality.
Cell lines and culture
A cell line (characterised as clone 10) from the murine colon
tumour Colon 26 was obtained from Dr Klohs (Warner-
Lambert, Ann Arbor, Michigan, USA) and was designated
Colon 26-10. Mycoplasma-free cells were maintained at 37°C
under an atmosphere of 5% CO2 as subconfluent monolayers
in 80 cm2 culture flasks (Nunclon, Denmark) and subcultured
once or twice weekly in Dulbecco's modification of Eagle's
medium (Flow Laboratories, Irvine, Scotland) supplemented
with 5% heat-inactivated foetal calf serum (FCS) (Gibco,
New York, USA) and 1 mM L-glutamine.
Drug sensitivity testing was performed in triplicate using a
modification of the Microculture Tetrazolium Assay (MTT
assay) described elsewhere (Keepers et al., 1991). Briefly, cells
were plated in 96-well flat bottom microtiterplates (Greiner
Labortechnik, Solingen, Germany) (100 til of cell suspension
per well) at optimal seeding densities (2,000-3,000 cells) to
assure exponential growth during the 4-day assay. After 48 h,
100 jil of culture medium or culture medium containing drug
was added to the wells. At the day of drug addition and at
the end of the culture period the MTT assay was performed.
briefly, MTT was added (0.5 mg ml-I final concentration) to
the wells, incubated for 2 h at 37°C, the medium was
removed and the formazan crystals formed were dissolved
with 150fld dimethylsulfoxide containing 0.5% FCS. The
absorbance was measured at 540 nm using a Titertek micro-
plate reader (Titertek Multiskan MCC/340, Flow
Laboratories, Irvine, Scotland).
Treatment ofmice
Colon 26 and Colon 38 are murine colon adenocarcinomas
maintained in 2-3 month old female Balb/c and C57B1/6
mice, respectively. Their sources and growth characteristics
have been described previously (Peters et al., 1987b, 1990b).
Tumours were transplanted as 1-5 mm3 fragments sub-
cutaneously in the flanks of the animals. Growth of the
tumours was determined by caliper measurement (length x
width x thickness x 0.5) once to twice a week. Treatment
was started when tumour volume was between 50 and
150 mm3 (19 days after transplantation for Colon 38 and 10
days for Colon 26). The volume of the tumours was cal-
culated relative to that of the first day of treatment (day 0).
Before treatment mice were randomised in groups of each six
animals. The antitumour effect was evaluated by using the
T/C (volume of treated tumours divided by that of control
tumours) and the growth delay factor (Peters et al., 1990b):
GDF = (TDTR-TDC)/TDc, where TDTR is the tumour doubling
time of tumours from treated mice and TDc that from
untreated mice.
Results
In vitro studies
From previous studies it was evident that endogenous
nucleosides and bases present in cell culture medium and
serum may prevent/rescue the growth-inhibitory effects of
Brequinar and may influence the action of 5FU. So, several
experiments on the effects of uridine and the interaction of
Brequinar and 5FU were performed with dialysed serum.
With reverse phase HPLC analysis no uridine (below detec-
tion limit of 0.1 SAM) could be demonstrated in this serum,
while in medium with 5% non-dialysed serum, the uridine
concentration was about 1-21iM. Figure 2 shows the effect
of uridine addition to the cell cultures. Even at a low uridine
concentration of 5tiM comparable to that in plasma, preven-
tion of the growth-inhibitory effects of Brequinar was
observed. This low concentration of exogenous uridine was
clearly sufficient to support nucleic acid synthesis for the
duration of the culture, even though uridine in the medium
decreased. At higher uridine concentrations comparable to
those in tissues complete reversal of growth-inhibition was
observed until Brequinar concentrations of 20-30t1M. How-
ever, above a certain threshold (>50JiM) concentration of
Brequinar no reversal could be observed.
For other inhibitors of pyrimidine de novo synthesis it has
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Figure 2 Effect of different concentrations of uridine (UR) on
the growth inhibition of Colon 26-10 cells by Brequinar.
Experiments were carried out in medium with 5% uridine-
depleted dialysed serum; the figure shows representative curves of
one experiment in which all combinations were tested. The IC50
values are 0.26 ± 0.04, 34± 4.5, 36± 5 and 40± 2JAM Brequinar
for cultures without addition of exogenous uridine, and after
addition of 5, 50 and 50011M, respectively. Values are means
± SE of 4-7 separate experiments. After 24 h these uridine con-
centrations decreased to not detectable (n.d.), 11 and 312JIM, respectively; and after 48 h to n.d., n.d. and 128JAM, respectively.
O 0 no UR; *--- * +5 laM UR; x x + 50jAM UR; ---0 + 500 JM UR.
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been shown that inhibition of the uptake of uridine would
enhance their cytoxicity (Grem et al., 1988). This also holds
for Brequinar (Figure 3). A non-toxic concentration of the
nucleoside transport-inhibitor dipyridamole enhanced growth
inhibition of Brequinar in the absence and presence of 1 or
10 JIM uridine. However, dipyridamole failed to enhance the
effect of Brequinar in the presence of 50,iM uridine.
Since uridine can influence the growth-inhibitory effect of
both Brequinar and 5FU we investigated this combination in
the absence and presence of uridine. 5FU was administered
2 h after Brequinar since we had previously demonstrated
that at this time point pyrimidine nucleotides were depleted
and DHO-DH was inhibited. Brequinar at 0.3 JiM was
equitoxic to the combination of 10 iM Brequinar in the
presence of 50 JIM added uridine (Figure 4). In the absence of
uridine the growth-inhibitory effect of Brequinar and 5FU
was more than would be expected in case of additive growth-
inhibition (47%0 growth). However, in the presence of uridine
only an additive effect was observed, since growth inhibition
was comparable to the expected growth-inhibition.
In vivo studies
For in vivo studies several schedules of Brequinar and 5FU
were tested. The most effective schedule for administration of
Brequinar to tumour-bearing mice was the daily schedule
(Braakhuis et al., 1990), while a schedule every 4 days
showed some activity in Colon 38 and no activity in Colon
26. 5FU at its MTD (100mg kg-' weekly for 4 weeks) was
very active against Colon 38, there was only minor activity
against Colon 26. For administration of 5FU every 4 days
the MTD was 60 mg kg-'. Therefore we compared the
weekly and every 4 day schedules. Simultaneous administra-
tion of both drugs at their MTD in a weekly schedule
resulted in an additive toxicity, as well as the combination at
an interval of 1 h (data not shown).
An interval of 4 h, being the time point at which inhibition
of DHO-DH by Brequinar is most pronounced (Peters et al.,
1990b), was evaluated more in detail at several dosages
(Table I). The weekly MTD dose of single agent 5FU
(100 mg kg-') was too toxic in the combination with Bre-
quinar and was lowered to 60 mg kg-1, which resulted in
combination with Brequinar in a comparable toxicity as sin-
gle agent 5FU at 100mgkg-'. At a weekly schedule Bre-
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Figure 3 Effect of 5 JIM dipyridamol and additional uridine
(UR) (1, 5 and 501M) on the growth-inhibition of 1 jiM Bre-
quinar (DUP). Experiments were carried out in medium with 5%
non-dialysed serum, which contained 1.2 iM endogenous uridine.
Brequinar, dipyridamol and uridine were added simultaneously to
the cultures. Bars represent means ± SE of three separate
experiments.
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Figure 4 Effect of several combinations of Brequinar (DUP) and
5FU on growth of Colon 26 cells in the absence and presence of
50 JIM UR. 5FU was added 2 h after Brequinar as indicated by
the arrow. Experiments were carried out in uridine depleted
serum. When indicated, uridine was present during the whole
experiment and added simultaneously with the first drug. Bars
represent means ± SE of four separate experiments. The absence
of a bar for 10JIM DUP indicates a complete growth inhibition
(% growth is <0).
quinar (at 50 mg kg-') showed no activity in Colon 38 while
the combination of Brequinar with 5FU was slightly more
active but also somewhat more toxic than 5FU alone (Table
I). At the q4d x 4 schedule Brequinar showed some activity
against Colon 38, while 5FU (at 60 mg kg-') was more
active. Although the combination was very active, toxicity
was very severe (Table I). However, the same schedule was
less toxic in Balb-c mice bearing Colon 26. Brequinar was
inactive against this tumour, while 5FU showed some activity
at the q4d x 4 schedule. The combination was very active.
Discussion
Biochemical modulation has shown to be an effective way to
improve the antitumour effect of 5FU. Enhancement of the
activity of 5FU with Brequinar appeared to be feasible, but
was complicated by external and endogenous conditions both
in vitro and in vivo. Apparently the uridine concentrations
determine the response to Brequinar and interfere with the
potentiation of 5FU activity. In addition toxicity was difficult
to predict and thus to control.
Theoretically Brequinar would be an ideal compound to
modulate the effects of 5FU, as the drug is a very potent
inhibitor of the pyrimidine de novo nucleotide synthesis
(Chen et al., 1986; Peters et al., 1987a). A fundamental
requirement for in vivo application of biochemical modula-
tion is a clear-cut demonstration of the biochemical effects,
which has been fulfilled in the case of Brequinar (Peters et
al., 1987a, 1990b; Schwartsmann et al., 1988). However,
physiological concentrations of uridine can already prevent
growth-inhibition by Brequinar, but only at concentrations
lower than 30 ILM Brequinar. Even very high concentrations
of uridine can not reverse the cytotoxic effects of Brequinar.
Also dipyridamole, a nucleoside transport inhibitor, can
reduce the effects of uridine only partly. In contrast, the
cytotoxic effects of high concentrations of PALA and
pyrazofurin, could be reversed by uridine (Grem et al., 1988).
The lack of reversal of cytotoxicity of Brequinar at high
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Table I Antitumour effect and toxicity of the combination of Brequinar with
5FU in mice bearing Colon 26 and Colon 38
Dose Weight ILSI
Drug (mgkg-') Schedule GDF TIC (%) loss (%) LS
Colon 26
Breq 50 q7d x 3 -0.18 1.13 (8) 13 (8) 100
5FUa 100 q7d x 3 0.39a 0.62 (8) 10 (15) 154
B->Fa q7d x 3 1.50b 0.36 (8)a 12 (15) 162
Breq 50 q4d x 4 0.00 0.79 (8) 14 (8) 158
5FUa 60 q4d x 4 1.60a 0.39 (8)a 14 (8) 142
B->Fa q4d x 4 >2.7b 0.27 (8)b 14 (8) 100
Breq 50 q4d x 4 0.17 1.07 (7) 10 (8) 133
5FUa 60 q4d x 4 2.39b 0.42 (7)a 10 (8) 125
B->Fb q4d x 4 >2.7b 0.19 (7)b 14 (8) 142
Colon 38
Breq 50 q4d x 4 0.52c 0.40 (21)a <5 >40
5FUa 60 q4d x 4 2.99b 0.16 (14)b <5 >40
B->Fa q4d x 4 4.72b 0.02 (14)b 24 (12)b 14
Breq 50 q7d x 4 0.62a 0.52 (17)c <5 >40
5FUa 60 q7d x 4 2.39b 0.17 (17)b <5 >40
B->Fa q7d x 4 3.27b 0.08 (I7)b 7 (17)c >40
Breq, Brequinar sodium; B->F, Brequinar followed after 4 h by 5FU. T/C,
volume of treated tumours divided by that of control tumours; weight loss,
maximum loss in percentages of weight at the first day of treatment; within
parentheses the day at which these values were calculated. GDF, Growth Delay
Factor. ILS, increase in life-span, i.e. median life-span of treated mice divided by
that of non-treated mice x 100%, median life-span of non-treated mice bearing
Colon 26 after the first day of treatment was 12 days; that of mice bearing Colon
38 was more than 40 days, when tumour volume exeeded a size of 2,000 mm' the
experiment was discontinued. For Colon 26 the ILS is given, while for Colon 38
the life-span (LS) is given. Signs behind GDF, T/C and weight loss indicate the
level of significance of the difference between tumours of treated animals
compared to controls; b, <0.001; a, <0.01; c, <0.05. Signs in the first column
after 5FU and B->F indicates the significance levels of the difference between
Breq and 5FU and between 5FU and B->F, respectively.
concentrations and the different shape of the dose response
curves, make it very likely that at high concentrations of the
drug an additional mechanism of action may be responsible
for irreversible cytotoxicity (at least not reversible by
uridine). This additional target may be related to the first
target (inhibition of the mitochondrial enzyme DHO-DH)
leading to a dysfunctioning of the mitochondrial electron
transport system. In tissues this target may be affected since
6 h after treatment with 50 mg Brequinar kg-' the concentra-
tion of Brequinar still exceeded 50fLM in tumours and some
other tissues (Shen et al., 1988), with accompanying plasma
levels of >100 JiM.
In principle this knowledge of in vitro interaction may be
used for the design of in vivo modulation schedules. So, a
relatively low dose of Brequinar which is biochemically active
may be used for modulation of 5FU. However, scheduling
and dosing of both drugs appeared to be very important,
since at a weekly schedule at the MTD of 5FU, the toxicity
was too severe. However, the MTD for 5FU for a q4d
schedule could be combined with Brequinar. Several
parameters may determine the activity of the combination,
such as endogenous uridine concentrations. In Colon 38 the
uridine concentrations are higher (50-100jtM) than in Colon
26 (about 10;iM) (Peters et al., 1990, 1987b). Plasma concen-
trations ofuridine in mice are about 8.5 JiM. The in vitro data
have shown that high uridine concentrations will preclude a
possible synergistic effect. So, in Colon 38 only an additive
antitumour effect was observed, while toxicity was usually
enhanced. The latter may also be related to an additional
mechanism of action in Colon 38. This tumour is very nec-
rotic and it has been observed for other DHO-DH inhibitors
that cytotoxic effects may be enhanced under hypoxic condi-
tions (Loffler, 1980). In contrast, Colon 26 lacks necrosis and
a possible synergism is less likely to be precluded by high
uridine concentrations, because of the low uridine in this
tumour. So, in this tumour a potentiation of the activity of
5FU by modulating its mechanism may be possible. The
advantage of Brequinar compared to other inhibitors of
pyrimidine de novo synthesis may be the observation that
reversal by uridine is limited. It is not clear from these
studies how Brequinar would interact with 5FU, but it is
very likely that the incorporation of 5FU into RNA would
be enhanced, similar to the effect of PALA on 5FU
metabolism (Grem et al., 1988). A decrease of pyrimidine
deoxyribonucleotides including that of dUMP, would
enhance the inhibitory effect of FdUMP on thymidylate syn-
thase.
It may be concluded that the biochemical effects of Bre-
quinar are more complex than initial biochemical studies
indicated. An additional mechanism of action may exist at
high concentrations (>50 M) of Brequinar. At lower con-
centrations, which can already decrease pyrimidine nucleo-
tides, Brequinar may be able to potentiate the effect of 5FU,
depending on endogenous uridine concentrations. However,
the timing and dosing of both compounds is very critical.
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